VRDNViridian Therapeutics, Inc.

Ticker: VRDN | Price: $28.09 | Today's Change: +11.70% Filing: 10-Q | Filed with the SEC on: November 4, 2026

---

What Happened

Viridian Therapeutics filed its quarterly report (Form 10-Q) with the SEC on November 4, 2026, covering its third fiscal quarter of FY2026. The filing discloses a net loss of $86.9 million and an operating loss of $240.6 million for Q3 FY2026. These figures underscore the company's continued heavy investment phase, consistent with a clinical-stage biopharmaceutical company carrying significant research and development expenditures ahead of commercial milestones.

Why It Matters

For investors, the magnitude of the operating loss — $240.6 million in a single quarter — signals that Viridian remains in a high cash-consumption period. The gap between the net loss ($86.9M) and the operating loss ($240.6M) suggests meaningful non-operating offsets (such as interest income or investment gains on cash holdings) that partially cushion the bottom line, though the structured financial data provided does not break this down further. No revenue figure is reported for Q3 FY2026 in the structured XBRL data for the current period, reinforcing that the company is not yet generating material commercial revenue. Investors should monitor the company's remaining cash runway closely, as the pace of spending implied by this quarter's figures is substantial.

Key figures from the filing:

• Net Loss (Q3 FY2026): -$86,912,000
• Operating Loss (Q3 FY2026): -$240,646,000
• EPS Basic & Diluted (Q3 FY2024, as reported in XBRL): -$3.97 per share

Note: The EPS figures provided in the structured data are attributed to Q3 FY2024 and are included here as filed; current-period per-share data was not separately provided in the structured facts.

Analysis

The stock's sharp gain of +11.70% on the day of this report suggests the market may be reacting to news or data beyond the raw loss figures — potentially clinical or pipeline-related developments disclosed elsewhere in the 10-Q or in concurrent communications, though those details are not part of the structured financial data provided. That said, the financial picture itself remains consistent with what a development-stage biopharma carries: large operating losses driven by R&D investment, partially offset at the net income line by non-operating income.

StockWatch initiated coverage of VRDN on September 11, 2026; this quarterly filing represents the first major financial update since that initiation and provides a concrete data point on the company's spending trajectory heading into what is likely a pivotal pipeline period. The wide spread between operating loss and net loss warrants further examination of the company's balance sheet — specifically its cash, investments, and debt position — to assess how long the current capital base can sustain operations at this burn rate.

Investors should watch for:

• Pipeline readouts or clinical updates disclosed within the full 10-Q narrative (not captured in structured XBRL data here)
• Cash and equivalents balance to gauge remaining runway
• Any guidance or milestone commentary from management accompanying the filing

Disclaimer

This report is provided for informational and news purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Financial figures cited are sourced exclusively from Viridian Therapeutics' official XBRL-structured data as filed with the SEC. Readers should conduct their own due diligence and consult a qualified financial advisor before making any investment decisions.

Existing Coverage

StockWatch has full coverage on VRDN, published 2026-09-11. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-04. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000022/vrdn-20260930.htm